
United Therapeutics Corp
NASDAQ:UTHR

Intrinsic Value
The intrinsic value of one
UTHR
stock under the Base Case scenario is
284.17
USD.
Compared to the current market price of 276.47 USD,
United Therapeutics Corp
is
Undervalued by 3%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
United Therapeutics Corp
Fundamental Analysis

Significant reliance on its pulmonary arterial hypertension (PAH) franchise exposes United Therapeutics to competition from newer therapies and potential generic entrants, which could erode its leading market share and pricing power.
United Therapeutics has maintained a strong foothold in PAH treatments with established therapies such as Tyvaso, Orenitram, and Remodulin, supported by steady demand and favorable reimbursement, driving stable cash flow.

Revenue & Expenses Breakdown
United Therapeutics Corp
Balance Sheet Decomposition
United Therapeutics Corp
Current Assets | 3.9B |
Cash & Short-Term Investments | 3.3B |
Receivables | 322m |
Other Current Assets | 296.5m |
Non-Current Assets | 3.8B |
Long-Term Investments | 1.7B |
PP&E | 1.3B |
Intangibles | 111.7m |
Other Non-Current Assets | 679m |
Free Cash Flow Analysis
United Therapeutics Corp
USD | |
Free Cash Flow | USD |
Earnings Waterfall
United Therapeutics Corp
Revenue
|
3B
USD
|
Cost of Revenue
|
-329.3m
USD
|
Gross Profit
|
2.7B
USD
|
Operating Expenses
|
-1.3B
USD
|
Operating Income
|
1.4B
USD
|
Other Expenses
|
-192.8m
USD
|
Net Income
|
1.2B
USD
|
UTHR Profitability Score
Profitability Due Diligence
United Therapeutics Corp's profitability score is 74/100. The higher the profitability score, the more profitable the company is.

Score
United Therapeutics Corp's profitability score is 74/100. The higher the profitability score, the more profitable the company is.
UTHR Solvency Score
Solvency Due Diligence
United Therapeutics Corp's solvency score is 93/100. The higher the solvency score, the more solvent the company is.

Score
United Therapeutics Corp's solvency score is 93/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
UTHR Price Targets Summary
United Therapeutics Corp
According to Wall Street analysts, the average 1-year price target for
UTHR
is 399.49 USD
with a low forecast of 317.14 USD and a high forecast of 630 USD.
Dividends
Current shareholder yield for UTHR is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
UTHR
stock under the Base Case scenario is
284.17
USD.
Compared to the current market price of 276.47 USD,
United Therapeutics Corp
is
Undervalued by 3%.